Strategic Partners: Giner Life Sciences is interested in developing strategic partnerships with pharmaceutical, biotech, biomed and cell therapy companies for clinical and product development in T1D. We are also looking for partners in developing additional indications where implanted systems for gas generation may be of nutritional metabolic or cytoprotective value to implanted therapeutic cells or to native tissue.
Investors: Giner Life Sciences is seeking to initiate a Series A round to complete development of the oxygenated implant system for preclinical testing for treatment of Type 1 Diabetes.
Investment to Date: Development of the oxygenated cell implant system is currently funded using a combination of grant and investment from our parent company, Giner Inc. Grant support has come mainly through the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK grants totaling $2.5M : R43/R44 DK100999; R43 DK113536).
Additional support from NIH NIDDK has supported development of the portable organ preservation system (NIDDK grant number: R44 DK070400, R41DK108620).
